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Objectives. The aim of this study was to quantitatively measure
regional and global myocardial blood flow and coronary reserve in
hypertensive patients without coronary artery disease and to
assess the correlation with left ventricular mass.
Background. The effect of left ventricular hypertrophy on
regional vasodilating coronary capability in arterial hypertension
is controversial, and no quantitative method has been applied to
assess a possible correlation.
Methods. Positron emission tomography was performed in 50
untreated hypertensive patients and 13 normotensive subjects.
Blood flow at baseline and after dipyridamole was globally and
regionally measured by using nitrogen-13 ammonia; coronary
reserve and resistance were calculated. Left ventricular mass was
assessed by two-dimensional echocardiography.
Results. In hypertensive patients, flow at baseline was similar
to that of normotensive subjects (p 5 0.21), but values were
reduced after pharmacologic vasodilation (p < 0.05). This impair-
ment of maximal coronary flow was not correlated with left
ventricular mass (p 5 0.13). Among hypertensive patients, we
identified a group with a homogeneous distribution of perfusion
and a group with a heterogeneous flow pattern. Flow was globally
reduced in the former group, but it was abnormal only at the site
of perfusion defects in the latter. Patients with regional defects
showed the highest likelihood of having an increased left ventric-
ular mass.
Conclusions. In arterial hypertension, left ventricular mass is
not correlated with global myocardial blood flow. Nevertheless,
patients with ventricular hypertrophy are likely to show a heter-
ogeneous flow pattern with regional defects and almost normal
blood flow in nonaffected regions. In hypertensive patients with a
homogeneous perfusion pattern during stress, myocardial blood
flow frequently shows a diffuse reduction.
(J Am Coll Cardiol 1998;31:366–73)
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The presence of an abnormal coronary vasodilator reserve
despite angiographically normal coronary arteries in patients
with essential hypertension has been demonstrated by various
experimental and clinical studies (1–3). To explain this obser-
vation, several works attributed this finding to the effects of left
ventricular hypertrophy induced by hypertension. Possible
mechanisms included an increase in extravascular compressive
forces caused by hypertrophy and resulting in elevated systolic/
diastolic wall stress and impaired relaxation or structural
alterations such as myocyte hypertrophy, interstitial fibrosis
and rarefaction of coronary microvasculature leading to re-
duced myocardial blood flow (MBF) (2).
More recently, it has been shown (1,4) that the impairment
of coronary flow reserve in hypertensive patients is not neces-
sarily related to the presence or degree of left ventricular
hypertrophy. Vogt et al. (4), by using the argon washout
technique and echocardiography, observed in a group of
hypertensive patients that myocardial mass and overall mini-
mal coronary vascular resistance were not directly correlated.
These data indicated that the impairment of coronary reserve
is mainly caused by a reduction in the vasodilating capacity of
the coronary resistance vessels rather than by effects linked to
hypertrophy alone. This effect may be due to “vascular remod-
eling,” such as media thickening, perivascular fibrosis or
functional alterations linked to endothelial dysfunction (5–7).
Houghton et al. (8) performed measurements of coronary
flow reserve by Doppler technique in combination with exer-
cise thallium scintigraphy in hypertensive patients. Despite the
absence of a linear relation, left ventricular mass index
(LVMI) was significantly higher in patients with stress-induced
perfusion abnormalities than in patients with a negative thal-
lium study result. Additionally, patients with thallium-201
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defects had lower coronary vasodilator reserve. This observa-
tion suggests that stress-induced heterogeneity of perfusion is
caused by an abnormal vasodilating capacity and leads to a
mismatch between oxygen supply and demand in hypertrophic
hearts. Nevertheless, the lack of spatial correspondence be-
tween intracoronary Doppler flow measurements and the
results of thallium-201 scintigraphy, as well as the absence of
absolute MBF measurements, hampered the conclusions on
the relation among perfusion defects, regional coronary flow
reserve and LVMI in that study.
To date, no published studies have evaluated the correla-
tion among absolute regional MBF, impaired coronary flow
reserve and LVMI in hypertensive patients, with emphasis on
regional flow inhomogeneities. Evaluating regional aspects of
flow impairment may help to further elucidate the causes of
this phenomenon and thus contribute to a better understand-
ing of the relation between myocardial hypertrophy and re-
gional perfusion. Therefore, aim of the study was to investigate
in patients with essential hypertension the relation between
absolute MBF, quantified by positron emission tomography
(PET), and LVMI as assessed by echocardiography. Addition-
ally, regional aspects of blood flow were examined.
Methods
Study patients. The study group comprised 50 patients
(mean age 6 SD 56 6 8 years, range 43 to 76) with a first
diagnosis of mild to moderate arterial hypertension in the
absence of coronary artery disease. Coronary artery disease
was ruled out by the presence of normal coronary angiographic
results in 34 patients, and by negative findings on both maximal
stress exercise testing and high dose dipyridamole stress echo-
cardiography (9) in the remaining 16 patients.
Hypertensive patients had a casual diastolic blood pressure
reading, as measured by mercury manometer, $95 mm Hg.
None had ever received antihypertensive medical treatment;
thus, pharmacologic effects on hemodynamics, function or
ventricular hypertrophy could be ruled out. Patients who had
evidence of secondary hypertension or valvular, coronary or
primary myocardial disease were excluded. Thirteen normo-
tensive subjects, enrolled as a control group, were evaluated
with the same protocol. They were referred for coronary
angiography to exclude an organic cause of their atypical chest
pain. All had normal findings on physical examination, rest
electrocardiogram (ECG), echocardiogram, exercise stress
test, coronary angiography and left ventriculography. Age,
gender and race were similar in normotensive and hyperten-
sive subjects.
All patients were informed about the partially investigative
nature of the study and gave written informed consent to
participate. The study protocol was approved by the local
Ethical Committee on Human Studies.
PET study. A positron emission tomograph (ECAT III,
Siemens/CTI) providing three simultaneous cross sections of
the heart (two from the primary planes and one from the
interplane) was used. Regional MBF was assessed by N-13
ammonia at rest and during pharmacologic vasodilation with
dipyridamole. All patients were studied after an overnight fast;
caffeine and theophylline were withheld for $12 h before
imaging. Transmission scans of 60 million counts were ac-
quired and subsequently served to generate attenuation cor-
rection factors. Correct positioning was maintained through-
out the study by a light beam and indelible marks on the
patient’s torso. Thereafter, 7.4 MBq/kg body weight (0.2
mCi/kg) of N-13 ammonia was infused as a slow bolus over 10
to 20 s. Dynamic data acquisition started simultaneously with
tracer injection; 28 frames were acquired over 8 min (16
frames 3 3 s, 11 3 12 s and 1 3 300/s).
After acquisition of the baseline study, a period of 50 min
was allowed for the physical decay of N-13 ammonia. There-
after, dipyridamole (0.56 mg/kg over 4 min) was infused
intravenously under continuous ECG monitoring. This proto-
col was adopted because it has been shown (10) to induce
maximal vasodilation. The second N-13 ammonia flow study
was started 2 to 3 min after the end of dipyridamole infusion
with the same protocol as the baseline study. To antagonize the
effects of dipyridamole, aminophylline (120 to 240 mg) was
injected 3 min after N-13 ammonia injection in all patients.
MBF analysis. MBF was calculated according to a previ-
ously validated method (11,12). Briefly, only the transversal
plane visualizing the left ventricle at its best was analyzed. Into
each of the three walls—i.e., septal, anterior and posterolater-
al—two small regions of interest (25 to 30 voxels) were drawn
to calculate regional ammonia uptake, resulting in six regions
for each patient. The time curve of N-13 ammonia activity in
the arterial blood was computed with a small region of interest
placed in the left ventricular cavity.
Data values were corrected for decay and dead time loss. A
dedicated program was used to perform automatic edge de-
tection of the left ventricular wall to measure myocardial
thickness and to correct for the partial volume effect (11).
Regional MBF times N-13 ammonia extraction (rMBFe) was
calculated as
rMBFe 5 Cm 3 60/*0
`Cb~t! 3 dt,
where Cm and Cb are N-13 ammonia activity concentrations in
the myocardium in the last frame and in the arterial blood at
each time t, respectively. The Cb(t) curve was fitted by a
gamma variate function for integration. The rMBFe values
were then divided by tissue gravity (1.08 g/ml) to obtain the
real values in ml/min per g. Actual MBF values were calculated
from rMBFe by using the experimental relation between
ammonia uptake and microsphere-determined flow observed
in animal preparations (11).
Abbreviations and Acronyms
ECG 5 electrocardiogram, electrocardiographic
LVMI 5 left ventricular mass index
MBF 5 myocardial blood flow
PET 5 positron emission tomography
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To assess individual regional heterogeneity, percent values
for all regions of every patient were calculated. The 100%
reference value was assigned to the region with maximal flow.
To identify those regions with a perfusion defect during
maximal vasodilation, the average percent differences between
the minimal and the maximal flow for all six regions and its
relative standard deviations were calculated in the normal
study patients. Any region in the hypertensive patients having
an individual percent value lower than this difference plus 1 SD
was considered to have a perfusion defect.
Two-dimensional echocardiography. Two-dimensional echo-
cardiograms were performed in all patients by expert sonog-
raphers using commercially available echocardiographs with
2.5- to 3-MHz transducers. Left ventricular end-diastolic and
end-systolic cross-sectional diameters as well as septal and
posterolateral wall thickness were derived from M-mode im-
ages according to conventional criteria. Left ventricular vol-
umes were estimated from the end-diastolic and end-systolic
dimensions by using the formula of Teichholz et al. (13). LVMI
was calculated in end-diastole according to the Penn conven-
tion (14). Patients were considered to have ventricular hyper-
trophy when LVMI was .150 g/m2 in men and .120 g/m2 in
women (15). Accordingly, the hypertensive group was subdi-
vided into patients with normal LVMI and patients with
ventricular hypertrophy.
Because echocardiography permits reliable measurement
of only the wall thickness of the septal and posterolateral walls,
only those values were used to compare regional flow data with
echocardiographic data, resulting in the best possible spatial
match between echocardiographic and PET data. Relative wall
thickness was measured at end-diastole as the ratio of 2 3
posterior wall thickness/left ventricular end-diastolic diameter.
The presence of concentric or eccentric hypertrophy was
evaluated by using relative wall thickness and left ventricular
mass as previously described (16).
Statistical analysis. Data are presented as mean value 6
SD. For comparison of differences, the appropriate test for
independent or paired samples was employed. Comparison of
patients and normotensive subjects and comparison of blood
flow values in hypertensive patients with and without left
ventricular hypertrophy were performed by using analysis of
variance (ANOVA) and Newman-Keuls procedure for multi-
ple comparison. Chi-square analysis was performed to deter-
mine the significance in rate of occurrence. Least square linear
regression analysis was used to test the correlation between
dipyridamole flow and LVMI. The difference between corre-
lations was examined by one-way analysis of covariance. For all
comparisons, a p value , 0.05 was considered significant.
Results
Clinical findings. No serious side effects occurred as a
result of the study. In the hypertensive group, dipyridamole
injection caused chest pain in nine patients; ST segment
depression was observed in six. During dipyridamole infusion,
no significant changes were observed in blood pressure (sys-
tolic/diastolic blood pressure: 144/88 6 22/14 mm Hg vs.
145/92 6 21/13 mm Hg at baseline, p 5 0.18). By contrast,
dipyridamole increased heart rate significantly from 68 6 12
beats/min at baseline to 93 6 16 beats/min during pharmaco-
logic vasodilation (p , 0.01). Other clinical and demographic
data are reported in Table 1.
Echocardiographic findings. Mean LVMI in all hyperten-
sive patients was 149 6 33 g/m2 in men and 140 6 27 g/m2 in
women. Of the 50 hypertensive patients, 22 were classified as
without hypertrophy and 28 as with hypertrophy. In patients
without hypertrophy, mean LVMI was 125 6 15 g/m2 in men
and 106 6 5 g/m2 in women. In patients with hypertrophy,
LVMI was 173 6 23 g/m2 in men and 155 6 16 g/m2 in women;
mean diastolic thickness of the septal and posterolateral walls
was 13 6 2.4 mm and 12 6 1.4 mm, respectively. Regional wall
motion abnormalities, cavity dilation, left ventricular ejection
fraction ,50% or valvular disease was not observed in any
patient.
Global MBF, coronary reserve, coronary resistance and
correlation with LVMI in normotensive subjects and hyper-
tensive patients. In normotensive subjects, rest MBF was
1.09 6 0.2 ml/min per g and increased significantly after
dipyridamole (3.57 6 1.0 ml/min per g, p , 0.01). Coronary
reserve was 3.35 6 1.03, coronary resistance was 89 6 15 mm
Hg/ml per min per g at baseline and 27 6 8 mm Hg/ml per min
per g after pharmacologic vasodilation (p , 0.01).
In hypertensive patients, rest MBF was similar to the
baseline MBF of normal subjects (0.89 6 0.22 ml/min per g,
p 5 0.21), but after dipyridamole the increase in MBF was
significantly lower (2.18 6 0.75 ml/min per g, p , 0.05) than
the increase in normal subjects. Coronary reserve (2.51 6 0.88)
as well as coronary resistance (rest 134 6 33 mm Hg/ml per
min per g, minimal 57 6 19 mm Hg/ml per min per g) were
significantly different from values in normotensive subjects
(p , 0.05). In hypertensive patients with normal or elevated
LVMI, the increase in MBF after pharmacologic vasodilation,
coronary reserve, baseline and minimal coronary resistance
were significantly different from values in normotensive sub-
jects (all p , 0.05), whereas no difference was found in
baseline MBF (p 5 0.15) (Fig. 1). LVMI was not correlated
with mean basal flow, mean dipyridamole flow (r 5 20.22, p 5
Table 1. Demographic Characteristics*
Normotensive Subjects
(n 5 13)
Hypertensive Patients
(n 5 50)
Age (yr) 55 6 10 56 6 8
Body surface area (m2) 1.9 6 0.3 1.9 6 0.4
Body mass index (kg/m2) 26.5 6 4.5 26.4 6 5.1
Gender (male/female [no.]) 11/2 40/10
Cholesterol (mg/dl) 170 6 11 175 6 8
Diabetes (%) 0 0
Atypical angina (%) 0 3
End-diastolic diameter (mm) 48 6 9 50 6 8
*p 5 NS for all comparisons. Data presented are mean 6 SD, unless
otherwise indicated.
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0.13) (Fig. 2), coronary resistance (p 5 0.12 at baseline, p 5
0.09 after dipyridamole) or coronary reserve (p 5 0.35).
Regional MBF, coronary reserve and coronary resistance.
In the control subjects, mean rest and dipyridamole MBF were
highest in the septum and lowest in the posterolateral wall.
This difference did not reach statistical significance under
baseline conditions (p 5 0.13) but was significant after dipyr-
idamole (p , 0.05). Coronary reserve as well as baseline and
after dipyridamole coronary resistance were not significantly
different among the septal, anterior and posterolateral walls
(all p 5 NS).
In hypertensive patients, regional baseline MBF was similar
to that in normal subjects in all three ventricular walls, whereas
the regional flow values after pharmacologic vasodilation were
significantly lower (p , 0.05). The regional disparity was
analogous to that in the normotensive subjects, with flow
values highest in the septum and lowest in the posterolateral
wall (p 5 0.11 at baseline, p , 0.05 after dipyridamole).
Regional coronary reserve and coronary resistance before and
after dipyridamole for all three walls were significantly differ-
ent from values in the normotensive subjects (p , 0.05). No
significant differences in these variables (all p 5 NS) were
found between hypertensive patients with and without left
ventricular hypertrophy (Table 2).
Assessment of regional heterogeneity. Of 50 hypertensive
patients, 18 (group 1) showed regional flow heterogeneity after
dipyridamole, resulting in 29 of 108 regions displaying perfu-
sion defects. In the remaining 32 patients (group 2), 192 of 192
regions showed a homogeneous perfusion pattern. Groups 1
and 2 had similar clinical findings (gender, age, severity of
hypertension, chest pain, ECG changes). They also had similar
values for mean rest and dipyridamole MBF (0.84 6 0.18 vs.
0.93 6 0.94 ml/min per g at baseline [p 5 0.11] and 2.17 6 0.74
vs. 2.19 6 0.77 ml/min per g after dipyridamole [p 5 0.09]). In
addition, group 1 and 2 baseline values did not differ signifi-
cantly for coronary resistance (141 6 31 vs. 130 6 34 mm
Hg/ml per min per g [p 5 0.09], dipyridamole 58 6 22 vs. 56 6
18 mm Hg/ml per min per g [p 5 0.08]) or coronary reserve
(2.66 6 0.95 vs. 2.42 6 0.77 [p 5 0.08]). In group 1, mean MBF
after dipyridamole in the areas with perfusion defects was
significantly lower than the mean values in group 2 patients
with homogeneous perfusion. Maximal flow in group 1 was
similar to the value obtained in the normotensive subjects (p 5
0.11), whereas that in group 2 was significantly lower than that
in the normotensive group (p , 0.05, Fig. 3).
Of the 29 of 108 regions with an obvious perfusion deficit
after dipyridamole, 21 were located in the posterolateral wall
and 8 in the anterior wall; none was found in the septum. In the
remaining 79 of 108 regions of group 1, mean rest MBF was
0.98 6 0.3 ml/min per g (p 5 0.12 vs. values in normal sub-
Figure 1. Mean MBF (upper panel) and coronary resistance (lower
panel) in basal conditions (open bars) and after dipyridamole (shaded
bars). HT 5 hypertensive patients. *p , 0.05.
Figure 2. Correlation between LVMI and mean
dipyridamole MBF in all hypertensive patients.
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jects) and increased significantly after dipyridamole (2.8 6
0.9 ml/min per g, p 5 0.09 vs. values in normal subjects).
LVMI in patients with regional perfusion heterogeneity was
significantly higher than that obtained in patients with a
homogeneous perfusion pattern (156.2 6 37.7 vs. 141.4 6 26.6
g/m2, p , 0.05). Seven group 1 patients showed the most
severely elevated LVMI (.180 g/m2). Echocardiographic wall
thickness was not significantly different between the postero-
lateral and septal walls in group 1 patients (11.5 6 1.9 and
12.8 6 2.7 mm, respectively, p 5 0.33), and no significant
differences were observed between groups 1 and 2 with respect
to this variable. End-diastolic diameter was similar in groups 1
and 2 (50 6 5 mm vs. 49 6 6 mm, respectively, p 5 0.23).
Relative wall thickness was 0.48 6 0.06 in group 1 and 0.51 6
0.07 in group 2 (p 5 0.13). Fifty-five percent of patients with
regional flow heterogeneity and 45% of patients with a homo-
geneous perfusion pattern exhibited concentric hypertrophy
(p 5 0.11).
Discussion
In this study, an accurate method to measure specific MBF
(i.e., flow per unit of weight) was applied with the aim of
exploring the relation between LVMI and maximal coronary
vasodilating capability in hypertensive patients with normal
coronary arteries. Regional coronary resistance and coronary
reserve were also assessed.
Our results demonstrate that the vasodilating capability of
the coronary microvasculature in hypertensive patients with
normal coronary arteries is significantly impaired in compari-
son with that of a control group of normotensive subjects. This
global impairment is not directly linked to the presence or
degree of left ventricular hypertrophy as assessed by echocar-
diography.
Different patterns in the spatial distribution of this impair-
ment of vasodilating capability were elucidated when regional
aspects were analyzed. Two groups were identified among
hypertensive patients: In group 1, patients had heterogeneous
perfusion after dipyridamole, whereas patients in group 2 had
homogeneous MBF after pharmacologic vasodilation. In pa-
tients with perfusion defects, dipyridamole flow was within the
normal range in the scintigraphically normal territories. In
contrast, patients with homogeneous perfusion without re-
gional deficits demonstrated global flow impairment. In the
homogeneous group, 4 patients had severely reduced MBF
Table 2. Regional Values for Myocardial Blood Flow, Coronary
Reserve and Resistance
Normotensive
Subjects
Hypertensive Patients
With Normal
LVMI
With Elevated
LVMI
Baseline rMBF
Septum 1.2 6 0.3 0.95 6 0.2 1.15 6 0.25
Anterior 1.1 6 0.2 0.82 6 0.24 0.86 6 0.24
Posterolateral 1.03 6 0.17 0.79 6 0.25 0.84 6 0.21
Dipyridamole rMBF
Septum 4.23 6 1.39 2.47 6 0.97* 2.53 6 0.79*
Anterior 3.53 6 0.87 2.03 6 0.9* 2.02 6 0.66*
Posterolateral 3.2 6 0.89 1.89 6 0.71* 1.89 6 0.68*
Coronary reserve
Septum 3.6 6 1.3 2.6 6 1* 2.5 6 1.1*
Anterior 3.4 6 0.9 2.5 6 1* 2.4 6 0.8*
Posterolateral 3.2 6 0.9 2.4 6 0.7* 2.4 6 1*
Coronary resistance
(mm Hg/ml per min per g)
Baseline
Septum 82 6 16 123 6 26† 113 6 27†
Anterior 87 6 13 148 6 41† 140 6 37†
Posterolateral 93 6 16 155 6 49† 144 6 40†
Dipyridamole
Septum 24 6 9 50 6 19† 49 6 16†
Anterior 26 6 6 62 6 24† 61 6 21†
Posterolateral 29 6 7 65 6 24† 68 6 29†
*p , 0.05, †p , 0.01 versus normotensive subjects. Data presented are mean
value 6 SD. LVMI 5 left ventricular mass index (g/m2); rMBF 5 regional
myocardial blood flow (ml/min per g).
Figure 3. Maximal and minimal dipyridamole MBF in
normal subjects and in group 1 and 2 hypertensive
patients. Group 1 patients (heterogeneous flow pat-
tern) show abnormal flow values only in territories with
perfusion defects (minimal flow) during dipyridamole
with respect to findings in control subjects. Group 2
patients (homogeneous flow pattern) show homoge-
neously reduced flow values with respect to findings in
normal subjects. Mean maximal flow values are also
significantly lower than those observed in group 1. *p ,
0.05.
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after dipyridamole in all six regions analyzed, 11 had moder-
ately reduced MBF and the remaining 3 had flow within the
normal range.
No differences were found between patients with homoge-
neous and heterogeneous MBF by analyzing other variables
such as age, gender, severity of hypertension, heart rate under
basal conditions and after dipyridamole infusion, ischemic
ECG alterations or symptoms. In contrast, LVMI was signifi-
cantly higher in patients with regional hypoperfusion during
stress, thus indicating a link between the occurrence of re-
gional inhomogeneity and the degree of hypertrophy.
Mechanism for abnormal vasodilating capability in hyper-
tensive hearts. Several causes for the impairment of coronary
reserve in patients with arterial hypertension have been pos-
tulated (2,17–21). One may be a structural remodeling of the
coronary microvasculature and the accumulation of fibrillar
collagen in the myocardium (5,6). Vascular remodeling might
increase minimal resistance since it is associated with a reduc-
tion of arteriolar lumen (5). Maximal flow inhomogeneities
could indicate a different degree of remodeling in the myocar-
dial walls. Structural changes are associated with increased
expression of growth factors (22), matrix proteins (23) and
matrix proteinases (24). With respect to media thickening or
perivascular fibrosis, it is conceivable that these alterations are
not homogeneously distributed throughout the myocardium.
In addition, an increase in the extravascular component of
coronary resistance due to an augmentation of myocardial
tissue pressure during diastole (2,17) may contribute to im-
paired reserve, as suggested by previous study (18). A third
possible mechanism may be related to the effects of myocardial
hypertrophy (19–21). In concentric left ventricular hypertro-
phy, rest MBF in the epicardial vessel is increased to supply the
hypertrophied myocardium. A decreased capillary density and
a reduced flow reserve can be observed. It is conceivable that
MBF regulation in hypertrophied hearts might be affected by
various factors such as changes in oxygen consumption, vascu-
lar wall remodeling and changes in the extravascular compo-
nent of coronary resistance. The data of the present study show
that myocardial hypertrophy is associated with regional flow
heterogeneity; however, we observed no significant effect of
concentric hypertrophy on specific flow (i.e., flow per gram of
tissue) either at rest or during maximal vasodilation. In fact, a
reduced maximal flow capacity was also observed in nonhyper-
trophied hearts, while the correlation between left ventricular
mass and minimal resistance was not present.
Finally, a functional increase in the tone of the coronary
resistance vessels could be responsible for the decreased
coronary reserve. In the last years the endothelium has been
recognized as a major regulator of vascular tone and growth.
Both acute and chronic experimental hypertension are associ-
ated with reduced endothelium-dependent relaxation in re-
sponse to acetylcholine, adenosine diphosphate and, in large
vessels, thrombin (25). Human studies support these experi-
mental data (7,26). Furthermore, duration and severity of
hypertension may have an important effect on coronary flow
reserve (27). All of these theories represent possible explana-
tions for the reduced vasodilating capability in hypertensive
patients and the absence of correlation with left ventricular
hypertrophy. Nevertheless, none sufficiently clarifies the rela-
tion between myocardial hypertrophy and an abnormal vaso-
dilating capability.
The presence of left ventricular hypertrophy does represent
an indicator for those hypertensive patients who may show
stress-induced heterogeneous MBF. In a study by Geltman et
al. (28) in patients with angina and normal coronary arteries,
no regional MBF disparities were observed. Of their 17 study
patients, 7 were hypertensive but only 1 patient had left
ventricular hypertrophy. This discrepancy emphasizes the role
of hypertrophy for the development of regional heterogeneity.
In our study, hypertensive patients with homogeneous flow had
a high likelihood of displaying a diffuse reduction of maximal
flow after pharmacologic vasodilation. The pathophysiologic
mechanisms of this observation remain largely hypothetical. In
patients with heterogeneous regional MBF, the flow impair-
ment seems to affect only a few areas, whereas others seem to
be unaffected. In contrast, in patients with homogeneous MBF,
the whole myocardium displays a reduced vasodilating capa-
bility, thus possibly indicating a more advanced stage of the
disease.
Local functional alterations (such as hemodynamic pressure
overload) and local vasoactive substances (angiotensin II,
endothelin, prostaglandins), may play an important role in the
genesis of regional perfusion abnormalities. Molecular and
cellular biologic support for the important role of these
substances was offered recently (29,30) by the demonstration
of the “on switch” for cellular events that mediate cell growth
by proto-oncogenes. Functional alterations may display spatial
heterogeneity throughout the heart, thus affecting the micro-
vascular response regionally. These changes are associated
with structural alterations, such as endothelial dysfunction, as
evidenced by decreased endothelium-dependent relaxation
(7). To elucidate the role played by the mechanisms described,
studies that pay particular respect to regional rather than only
global effects of hypertension and hypertrophy on the coronary
microvasculature are warranted.
Comparison with previous studies. Published studies have
elucidated only a few aspects of the complex interactions
among hypertension, hypertrophy and regional MBF. Vogt et
al. (4), applying the argon method to examine the correlation
between MBF and myocardial hypertrophy, were able to assess
global MBF in basal conditions and during maximal vasodila-
tion and to calculate vascular resistance and coronary flow
reserve for the entire heart. They found no significant corre-
lation between flow data and echocardiographically assessed
LVMI. Because the argon method does not allow regional flow
evaluation, they could not clarify the regional aspects of flow
impairment in hypertensive patients. In contrast, Houghton et
al. (8) demonstrated that regional aspects may play an impor-
tant role. In agreement with Vogt et al. (4) they (8) found,
using Doppler catheter-derived coronary flow measurements,
no linear relation between flow reserve and the degree of left
ventricular hypertrophy. Nevertheless, they showed that hyper-
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tensive patients displaying thallium-201 perfusion defects had
a significantly lower coronary flow reserve and higher LVMI
than did with patients with negative scan results. They then
speculated that myocardial ischemia or hypoperfusion second-
ary to an effect of hypertrophy may be the basis for positive
thallium-201 findings. They concluded that although there is
no linear correlation between the decrease in coronary flow
reserve and the severity of left ventricular hypertrophy, the
presence of hypertrophy predicts those patients with a high
likelihood for positive thallium scan results. Because the
Doppler catheter technique permits assessment of flow veloc-
ity only in the territory of the catheterized coronary artery,
these authors also could not compare regional thallium-201
defects with regional flow measurements in the affected and
adjacent regions. Because of these methodologic drawbacks,
this group was unable to explain the paradoxic finding that
patients with hypertrophy show a higher incidence of positive
thallium findings despite the lack of a correlation between
ventricular mass and coronary flow.
Our results may explain this observation. As demonstrated,
there is a regional impairment of perfusion that is correlated
with ventricular mass and therefore may be the basis for
positive thallium findings in these patients. This regional flow
impairment can be identified only by assessing regional aspects
of MBF. The presence of “physiologic flow” during dipyrida-
mole infusion in some regions in patients with regional heter-
ogeneity results in a perfusion abnormality enhancement with
detectable perfusion defects. By contrast, a diffuse reduction in
MBF in patients with a homogeneous perfusion pattern results
in an apparently normal flow distribution. Calculation of mean
maximal flow (such as measurement of Doppler flow velocity
not necessarily linked to the site of perfusion abnormalities)
would not permit appreciation of differences between these
two perfusion patterns.
Clinical implications. The increased incidence of sudden
cardiac death and arrhythmias in hypertensive patients with
myocardial hypertrophy is well recognized. The findings of the
present study may offer a possible explanation for this phe-
nomenon. Spatial flow heterogeneity during pharmacologic
coronary vasodilation, most often observed in hypertrophic
hearts, may be the pathophysiologic mechanism underlying
malignant arrhythmias. It is possible that regional abnormal
vasodilating capability may predispose to abnormal patterns of
myocardial electrical depolarization and repolarization or re-
gional myocardial ischemia, or both, during increased cardiac
demand; these abnormal patterns might create a nidus for the
genesis of clinically important arrhythmias. If our results are
confirmed in future studies (which might even provide de facto
demonstration of regional ischemia), this observation may
warrant a different pharmacologic approach to the treatment
of hypertensive patients with myocardial hypertrophy, normal
coronary arteries and regional flow heterogeneity.
Another important effect of different perfusion patterns
could be their contribution to the modulation of left ventricu-
lar geometry. In a previous study (16), concentric remodeling
or eccentric hypertrophy was described as the effect of essen-
tial hypertension. In the present study, regional MBF hetero-
geneity was associated with left ventricular hypertrophy; how-
ever, we could not establish whether MBF heterogeneity is the
cause or the effect of left ventricular hypertrophy and of the
concentric remodeling. According to Ganau et al. (16), ven-
tricular chamber size and stroke volume may be influenced by
factors like blood volume, venous return, afterload and dia-
stolic or inotropic properties. The endothelial surface is par-
ticularly suited to play a prominent part in the vascular and
ventricular remodeling; in fact, it is constantly exposed to
humoral factors and physical forces. Thus, the endothelium is
strategically located to serve as a sensory cell assessing hemo-
dynamic and humoral signals, as well as an effector cell eliciting
biologic responses that may eventually affect the structure of
the vessels. These observations suggest that the differences in
regional vasodilating capability in hypertrophied hearts iden-
tified in this study may have an effect on the diastolic or
inotropic properties of the ventricle and thus contribute to the
development of ventricular remodeling.
Limitations of the study. One possible limitation of this
study is the use of N-13 ammonia as a flow tracer, because it
has been shown (31) that N-13 ammonia tends to underesti-
mate regional blood flow in the lateral wall even in normal
subjects. In fact, blood flow values in the lateral wall in our
patients were lower than in the remaining two ventricular
walls. The approach chosen to identify regions with severe flow
deficits should exclude effects of this technical limitation on the
results. However, the possible underestimation of lateral blood
flow in our study should not affect the calculation of regional
flow reserve, and therefore should not affect our results.
Another study limitation is that no follow-up data are available
in our patients, thus preventing assessment of the link between
reduced MBF and future events as well as of differences in the
prognosis of patients with homogeneous or heterogeneous
perfusion patterns during pharmacologic stress.
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